Hospitalization Risk from Onglyza Heart Failure Questioned in New Study
The findings of a new study claiming Onglyza does not cause heart failure are in contrast to findings by a panel of FDA experts who want new warnings placed on…
The findings of a new study claiming Onglyza does not cause heart failure are in contrast to findings by a panel of FDA experts who want new warnings placed on…
A federal judge has been asked to enter summary judgement in failure to warn lawsuits filed over the pancreatic cancer risk with Byetta, Januvia, Janumet and Victoza, arguing that the…
Some diabetes drugs unexpected linked to heart failure risks, new report finds.
A new study failed to find links between Januvia and increased cardiovascular risks.
An FDA advisory panel has voted to add new label warnings to the diabetes drug Nesina.
An FDA advisory committee is calling on the agency to add new warning labels to the diabetes drug Onglyza, including warnings of risks of heart failure and death.
FDA reviewers warn that the diabetes drug Onglyza may increase the risk of death in some patients.
A new study links blood glucose levels to an increased risk of pancreatic cancer.
A new report highlights problems with the FDA's drug approval and postmarketing monitoring processes, focusing on the side effects of diabetes drugs like Byetta, Januvia and Victoza.
A federal judge has rejected a call for access to source data on adverse event reports tied to some diabetes drugs and pancreatic cancer, saying it would lead to the…